harrow health, inc., together with its subsidiaries, develops, produces, and sells medications for unmet needs primarily in the united states. the company primarily provides ophthalmology based formulations to physicians and patients; and sterile and non-sterile compounded medications. it also develops and commercializes therapeutics for treating ocular surface diseases; and non-intravenous sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. its products portfolio includes topical eye drop drug candidates, including surf-100 and surf-200; surf-300, an oral capsule for treating patients suffering from ocular surface diseases, and ded signs and symptoms; klarity drops to protect and rehabilitate the ocular surface pathology for patients with ded; melt-100, a drug that is administered sublingually for conscious sedation during cataract surgery; may-66 that is used for the treatment of symptoms associated with peyronie's diseas
Company profile
Ticker
HROW, HROWL, HROWM
Exchange
Website
CEO
Mark L. Baum
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Bywater Resources, Inc, HARROW HEALTH, INC., Imprimis Pharmaceuticals, Inc., TRANSDEL PHARMACEUTICALS INC
SEC CIK
Corporate docs
Subsidiaries
ImprimisRx, LLC • Imprimis NJOF, LLC • ImprimisRx NJ, LLC • Harrow Eye, LLC • Harrow IP, LLC • ImprimisRx Nashville, LLC • Harrow Analytical Services, LLC ...
IRS number
450567010
HROW stock data
Latest filings (excl ownership)
8-K
Other Events
21 Mar 24
8-K
Other Events
20 Mar 24
8-K
Harrow Announces Fourth Quarter and Year-End 2023 Financial Results
19 Mar 24
10-K
2023 FY
Annual report
19 Mar 24
8-K
Harrow Licenses Canadian Rights to Apotex For Five Branded Ophthalmic Pharmaceutical Products
15 Feb 24
8-K
Harrow Announces New Appointments to its Board of Directors
29 Jan 24
8-K
Melt Pharmaceuticals Provides Corporate Update
3 Jan 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
Harrow Announces Third Quarter 2023 Financial Results
13 Nov 23
8-K
Departure of Directors or Certain Officers
3 Nov 23
Transcripts
HROW
Earnings call transcript
2023 Q4
20 Mar 24
HROW
Earnings call transcript
2023 Q3
13 Nov 23
HROW
Earnings call transcript
2023 Q2
9 Aug 23
HROW
Earnings call transcript
2023 Q1
11 May 23
HROW
Earnings call transcript
2022 Q4
23 Mar 23
HROW
Earnings call transcript
2022 Q3
14 Nov 22
HROW
Earnings call transcript
2022 Q2
14 Aug 22
HROW
Earnings call transcript
2022 Q1
9 May 22
HROW
Earnings call transcript
2021 Q4
11 Mar 22
HROW
Earnings call transcript
2021 Q3
10 Nov 21
Latest ownership filings
4
Change in insider ownership
19 Apr 24
4
Change in insider ownership
28 Mar 24
4
MARK L BAUM
25 Mar 24
4
Change in insider ownership
22 Mar 24
4
JOHN P. SAHAREK
6 Mar 24
4
JOHN P. SAHAREK
21 Feb 24
4
ANDREW R. BOLL
21 Feb 24
4
MARK L BAUM
21 Feb 24
SC 13G/A
Kaufman Daniel Louis
13 Feb 24
SC 13G
VANGUARD GROUP INC
13 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 65.61 mm | 65.61 mm | 65.61 mm | 65.61 mm | 65.61 mm | 65.61 mm |
Cash burn (monthly) | (no burn) | (no burn) | 950.67 k | 1.32 mm | 402.67 k | 714.00 k |
Cash used (since last report) | n/a | n/a | 6.35 mm | 8.80 mm | 2.69 mm | 4.77 mm |
Cash remaining | n/a | n/a | 59.26 mm | 56.81 mm | 62.92 mm | 60.84 mm |
Runway (months of cash) | n/a | n/a | 62.3 | 43.1 | 156.3 | 85.2 |
Institutional ownership, Q3 2023
70.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 126 |
Opened positions | 25 |
Closed positions | 8 |
Increased positions | 51 |
Reduced positions | 29 |
13F shares | Current |
---|---|
Total value | 354.80 bn |
Total shares | 24.74 mm |
Total puts | 318.90 k |
Total calls | 62.70 k |
Total put/call ratio | 5.1 |
Largest owners | Shares | Value |
---|---|---|
Opaleye Management | 3.80 mm | $54.53 bn |
BLK Blackrock | 2.03 mm | $29.16 bn |
Braidwell | 1.81 mm | $25.99 bn |
MS Morgan Stanley | 1.78 mm | $25.54 bn |
Vanguard | 1.76 mm | $25.29 bn |
Private Capital Management | 1.42 mm | $20.36 bn |
Renaissance Technologies | 951.06 k | $13.79 bn |
Driehaus Capital Management | 801.93 k | $11.52 bn |
STT State Street | 688.67 k | $9.90 bn |
Geode Capital Management | 616.60 k | $8.86 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
19 Apr 24 | Opaleye Management | Common Stock, par value $0.001 per share | Buy | Acquire P | Yes | No | 10.5575 | 29,400 | 310.39 k | 3,775,000 |
28 Mar 24 | Opaleye Management | Common Stock, par value $0.001 per share | Buy | Acquire P | Yes | No | 12.82 | 50,000 | 641.00 k | 3,745,600 |
22 Mar 24 | Baum Mark L | Common stock | Buy | Acquire P | No | No | 11.59 | 9,000 | 104.31 k | 2,137,525 |
20 Mar 24 | Opaleye Management | Common Stock, par value $0.001 per share | Buy | Acquire P | Yes | No | 9.65 | 50,600 | 488.29 k | 3,695,600 |
1 Mar 24 | John P. Saharek | Common stock | Option exercise | Acquire M | No | No | 8.75 | 5,000 | 43.75 k | 254,803 |
1 Mar 24 | John P. Saharek | Stock Option Common Stock | Option exercise | Dispose M | No | No | 8.75 | 5,000 | 43.75 k | 0 |
News
Craig-Hallum Initiates Coverage On Harrow with Buy Rating, Announces Price Target of $24
11 Apr 24
Insiders Buying Greenwich LifeSciences And 2 Other Stocks
25 Mar 24
Why Lifecore Biomedical Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
20 Mar 24
Why Taysha Gene Therapies Shares Are Trading Higher By Around 27%; Here Are 20 Stocks Moving Premarket
20 Mar 24
Harrow Posts Weak Q4 Results, Joins TeraWulf, Nasdaq And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
20 Mar 24